These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 8354118)

  • 41. Prognostic value of static cytometry in transitional cell carcinoma of the bladder: recurrence rate and survival in a group of patients at 10 years follow-up.
    Cai T; Margallo E; Nesi G; Giubilei G; Rizzo M; Bartoletti R
    Oncol Rep; 2006 Jan; 15(1):213-9. PubMed ID: 16328058
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Bladder cancer: diagnosis and prognosis--molecularbiological approach for prognostic factors. Discussion].
    Nihon Hinyokika Gakkai Zasshi; 1995 Jan; 86(1):55-65. PubMed ID: 7897922
    [No Abstract]   [Full Text] [Related]  

  • 43. [Clinical application of flow cytometry in lung cancer].
    Miyamoto H; Isobe H; Kawakami Y
    Kokyu To Junkan; 1988 Dec; 36(12):1291-8. PubMed ID: 3249843
    [No Abstract]   [Full Text] [Related]  

  • 44. Flow cytometric evaluation of early invasive cervical cancer.
    Connor JP; Miller DS; Bauer KD; Murad TM; Rademaker AW; Lurain JR
    Obstet Gynecol; 1993 Mar; 81(3):367-71. PubMed ID: 8437788
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic significance of DNA flow cytometric analysis in patients with nasopharyngeal carcinoma.
    Yip TT; Lau WH; Chan JK; Ngan RK; Poon YF; Lung CW; Lo TY; Ho JH
    Cancer; 1998 Dec; 83(11):2284-92. PubMed ID: 9840527
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Flow cytometry in ORL cancers].
    Michels JJ; Rame JP; de Raucourt D; Marnay J; Duigou F; Macé-Lesec'h J; Henry-Amar M; Mandard AM
    Bull Cancer; 1997 Jul; 84(7):693-8. PubMed ID: 9339194
    [TBL] [Abstract][Full Text] [Related]  

  • 47. DNA ploidy and S-phase fraction by image and flow cytometry in breast cancer fine-needle cytopunctures.
    Spyratos F; Briffod M
    Mod Pathol; 1997 Jun; 10(6):556-63. PubMed ID: 9195572
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Silver-stained nucleolar organizer regions in normal and dysplastic cervical lesions: correlation with DNA ploidy and S-phase fraction by flow cytometry.
    Singh M; Prasad S; Kalra N; Singh U; Shukla Y
    Oncology; 2006; 71(5-6):411-6. PubMed ID: 17785995
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Flow cytometry in cancer research].
    Eerola E; Joensuu H; Klemi PJ
    Duodecim; 1986; 102(12):792-8. PubMed ID: 3732101
    [No Abstract]   [Full Text] [Related]  

  • 50. Combined flow cytometry determination of S-phase fraction and DNA ploidy is an independent prognostic factor in node-negative invasive breast carcinoma: analysis of a series of 271 patients with stage I and II breast cancer.
    Moureau-Zabotto L; Bouchet C; Cesari D; Uzan S; Lefranc JP; Antoine M; Genestie C; Deniaud-Alexandre E; Bernaudin JF; Touboul E; Fleury-Feith J
    Breast Cancer Res Treat; 2005 May; 91(1):61-71. PubMed ID: 15868432
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nm23-H1 protein, DNA-ploidy and S-phase fraction in relation to overall survival and disease free survival in transitional cell carcinoma of the bladder.
    Alderisio M; Cenci M; Valli C; Russo A; Bazan V; Dardanoni G; Cucciarre S; Carreca I; Macaluso MP; Tomasino RM; Vecchione A
    Anticancer Res; 1998; 18(6A):4225-30. PubMed ID: 9891471
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [DNA flow cytrometry in solid tumors].
    Pinto AE; Fonseca I; Soares J
    Acta Med Port; 2002; 15(2):133-42. PubMed ID: 15524158
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Cellular biological approach for determining of malignant potential and invasiveness of bladder cancers].
    Tachibana M
    Nihon Hinyokika Gakkai Zasshi; 1996 Mar; 87(3):629-42. PubMed ID: 8709439
    [No Abstract]   [Full Text] [Related]  

  • 54. EORTC Genitourinary Group Monograph 3: Developments in bladder cancer. Proceedings of the First International Consensus Development Conference on Guidelines for Clinical Research in Bladder Cancer. Antwerp, Belgium, June 20-22, 1985.
    Prog Clin Biol Res; 1986; 221():1-328. PubMed ID: 3543940
    [No Abstract]   [Full Text] [Related]  

  • 55. Flow cytometry of urinary bladder irrigation specimens.
    Melamed MR; Klein FA
    Hum Pathol; 1984 Apr; 15(4):302-5. PubMed ID: 6714963
    [No Abstract]   [Full Text] [Related]  

  • 56. Apoptosis and its clinical significance for bladder cancer therapy.
    Kelly JD; Williamson KE; Irvine AE; Hamilton PW; Weir HP; Anderson NH; Keane PF; Johnston SR
    BJU Int; 1999 Jan; 83(1):1-10. PubMed ID: 10233445
    [No Abstract]   [Full Text] [Related]  

  • 57. Bladder tumour treatment in the aarhus region. 25 years of experience.
    Sell A; Jakobsen A; Mommsen S; Steenholdt S
    Scand J Urol Nephrol Suppl; 1989; 125():107-14. PubMed ID: 2699071
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The value of DNA analysis of solid tumors. A review for the clinically active pathologist].
    Steinbeck R; Askensten U; Auer G
    Pathologe; 1989 May; 10(3):171-6. PubMed ID: 2662169
    [No Abstract]   [Full Text] [Related]  

  • 59. [Bladder tumors: current prognostic factors].
    Sohet X
    Acta Urol Belg; 1995 Mar; 63(1):61-71. PubMed ID: 7725994
    [No Abstract]   [Full Text] [Related]  

  • 60. [The value of DNA flow cytometry in solid tumors].
    Rodenburg CJ; Cornelisse CJ; Fleuren GJ
    Ned Tijdschr Geneeskd; 1989 Apr; 133(16):814-8. PubMed ID: 2725735
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.